EZH2 and breast cancer: Mutations in these genes have been reported to confer sensitivity to PARPi38,40, CDK4/6 inhibitors71, EZH2 inhibitor72, RET inhibitors73 and combination tyrosine kinase inhibitors with immunotherapy74, respectively, in studies on BC as well as other solid tumours.